The EDGE

How to manage primary amyloidosis

M A Gertz

Leukemia 2012 26: 191-198; advance online publication, August 26, 2011; 10.1038/leu.2011.219

Reviews

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

N W C J van de Donk, S Kamps, T Mutis and H M Lokhorst

Leukemia 2012 26: 199-213; advance online publication, August 19, 2011; 10.1038/leu.2011.214

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy

P J Shami and M Deininger

Leukemia 2012 26: 214-224; advance online publication, August 16, 2011; 10.1038/leu.2011.217

Original Articles

ACUTE LEUKEMIAS

Absence of IL-12Rβ2 in CD33⁺CD38⁺ pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice

E Ferretti, D Montagna, E Di Carlo, C Cocco, D Ribatti, E Ognio, C Sorrentino, D Lisini, A Bertaina, F Locatelli, V Pistoia and I Airoldi

Leukemia 2012 26: 225-235; advance online publication, August 16, 2011; 10.1038/leu.2011.213

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

K C Goh, V Novotny-Diermayr, S Hart, L C Ong, Y K Loh, A Cheong, Y C Tan, C Hu, R Jayaraman, A D William, E T Sun, B W Dymock, K H Ong, K Ethirajulu, F Burrows and J M Wood

Leukemia 2012 26: 236-243; advance online publication, August 23, 2011; 10.1038/leu.2011.218

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors

S Negrotto, K P Ng, A M Jankowska, J Bodo, B Gopalan, K Guinta, J C Mulloy, E Hsi, J Maciejewski and Y Saunthararajah

Leukemia 2012 26: 244-254; advance online publication, August 12, 2011; 10.1038/leu.2011.207

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells

J F de Vries, C M Zwaan, M De Bie, J S A Voerman, M L den Boer, J J M van Dongen and V H J van der Velden

Leukemia 2012 26: 255-264; advance online publication, August 26, 2011; 10.1038/leu.2011.206

ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy

D Bhojwani, D Pei, J T Sandlund, S Jeha, R C Ribeiro, J E Rubnitz, S C Raimondi, S Shurtleff, M Onciu, C Cheng, E Coustan-Smith, W P Bowman, S C Howard, M L Metzger, H Inaba, W Leung, W E Evans, D Campana, M V Relling and C-H Pui

Leukemia 2012 26: 265-270; advance online publication, August 26, 2011; 10.1038/leu.2011.227

Endogenous knockdown of survivin improves chemotherapeutic response in ALL models

D J Morrison, L E Hogan, G Condos, T Bhatla, N Germino, N P Moskowitz, L Lee, D Bhojwani, T M Horton, I Belitskaya-Levy, L M Greenberger, I D Horak, S A Grupp, D T Teachey, E A Raetz and W L Carroll

Leukemia 2012 26: 271-279; advance online publication, August 16, 2011; 10.1038/leu.2011.199

CHRONIC MYELOPROLIFERATIVE NEOPLASIAS

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2

A V Purandare, T M McDevitt, H Wan, D You, B Penhallow, X Han, R Vuppugalla, Y Zhang, S U Ruepp, G L Trainor, L Lombardo, D Pedicord, M M Gottardis, P Ross-Macdonald, H de Silva, J Hosbach, S L Emanuel, Y Blat, E Fitzpatrick, T L Taylor, K W McIntyre, E Michaud, C Mulligan, F Y Lee, A Woolfson, T L Lasho, A Pardanani, A Tefferi and M V Lorenzi

Leukemia 2012 26: 280-288; advance online publication, October 21, 2011; 10.1038/leu.2011.292

CYTOGENETICS AND MOLECULAR GENETICS

Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia

F Damm, T Bunke, F Thol, B Markus, K Wagner, G Göhring, B Schlegelberger, G Heil, C W M Reuter, K Püllmann, R F Schlenk, K Döhner, M Heuser, J Krauter, H Döhner, A Ganser and M A Morgan

Leukemia 2012 26: 289-295; advance online publication, August 9, 2011; 10.1038/leu.2011.200

IMMUNOLOGY

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib

D Marin, I H Gabriel, S Ahmad, L Foroni, H de Lavallade, R Clark, S O'Brien, R Sergeant, C Hedgley, D Milojkovic, J S Khorashad, M Bua, A Alsuliman, A Khoder, K Stringaris, N Cooper, J Davis, J M Goldman, J F Apperley and K Rezvani

Leukemia 2012 26: 296-302; advance online publication, August 16, 2011; 10.1038/leu.2011.180

ONCOGENES, FUSION GENES AND TUMOR SUPPRESSOR GENES

C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells

Y Satoh, I Matsumura, H Tanaka, H Harada, Y Harada, K Matsui, M Shibata, M Mizuki and Y Kanakura

Leukemia 2012 26: 303-311; advance online publication, August 12, 2011; 10.1038/leu.2011.202

ANIMAL MODELS

Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia

S Stevanović, M Griffioen, B A Nijmeijer, M L J van Schie, A N Stumpf, C E Rutten, R Willemze and J H F Falkenburg

Leukemia 2012 26: 312-322; advance online publication, August 23, 2011; 10.1038/leu.2011.222

LYMPHOMA

Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1

R C T McKenzie, C L Jones, I Tosi, J A Caesar, S J Whittaker and T J Mitchell

Leukemia 2012 26: 323-331; advance online publication, August 5, 2011; 10.1038/leu.2011.198

Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b⁺/F4/80⁺ myeloid cell recruitment

M Ishihara, C Nishida, Y Tashiro, I Gritli, J Rosenkvist, M Koizumi, Y Okaji, R Yamamoto, H Yagita, K Okumura, M Nishikori, K Wanaka, Y Tsuda, Y Okada, H Nakauchi, B Heissig and K Hattori

Leukemia 2012 26: 332-339; advance online publication, September 20, 2011; 10.1038/leu.2011.203

MYELOMA

MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma

V Ramakrishnan, S Ansell, J Haug, D Grote, T Kimlinger, M Stenson, M Timm, L Wellik, T Halling, S V Rajkumar and S Kumar

Leukemia 2012 26: 340-348; advance online publication, August 9, 2011; 10.1038/leu.2011.192

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

K D Boyd, F M Ross, L Chiecchio, G P Dagrada, Z J Konn, W J Tapper, B A Walker, C P Wardell, W M Gregory, A J Szubert, S E Bell, J A Child, G H Jackson, F E Davies and G J Morgan on behalf of the NCRI Haematology Oncology Studies Group

Leukemia 2012 26: 349-355; advance online publication, August 12, 2011; 10.1038/leu.2011.204

Letters to the Editor

Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide

G Göhring, K Lange, W Hofmann, K V Nielsen, E Hellström-Lindberg, L Roy, M Morgan, H Kreipe, G Büsche, A Giagounidis and B Schlegelberger

Leukemia 2012 26: 356-358; advance online publication, July 29, 2011; 10.1038/leu.2011.193

High Epstein–Barr virus-specific T-cell counts are associated with near-zero likelihood of acute myeloid leukemia relapse after hematopoietic cell transplantation

M Hoegh-Petersen, S Sy, A Ugarte-Torres, T S Williamson, M Eliasziw, A Mansoor, Y Liu, S Liu, P Podgorny, F Khan, P R Duggan, D A Stewart, J A Russell and J Storek

Leukemia 2012 26: 359-362; advance online publication, July 29, 2011; 10.1038/leu.2011.195

Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML

A van der Jagt, J Muirhead, J F Seymour, K F Bradstock, E Paul and A Wei

Leukemia 2012 26: 362-365; advance online publication, August 12, 2011; 10.1038/leu.2011.201

T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells

K Mihara, J Bhattacharyya, A Kitanaka, K Yanagihara, T Kubo, Y Takei, H Asaoku, Y Takihara and A Kimura

Leukemia 2012 26: 365-367; advance online publication, August 12, 2011; 10.1038/leu.2011.205

DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL

M D Kraszewska, M Dawidowska, N S D Larmonie, M Kosmalska, Ł Sędek, M Szczepaniak, W Grzeszczak, A W Langerak, T Szczepański and M Witt members of the Polish Pediatric Leukemia Lymphoma Study Group (PPLLSG)

Leukemia 2012 26: 367-371; advance online publication, August 12, 2011; 10.1038/leu.2011.208

Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model

I H I M Hollink, Q Feng, A A Danen-van Oorschot, S T C J M Arentsen-Peters, L J Verboon, P Zhang, V de Haas, D Reinhardt, U Creutzig, J Trka, R Pieters, M M van den Heuvel-Eibrink, J Wang and C M Zwaan

Leukemia 2012 26: 371-373; advance online publication, August 12, 2011; 10.1038/leu.2011.210

Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population

T D Shanafelt, N E Kay, K G Rabe, T G Call, C S Zent, S M Schwager, J F Leis, D F Jelinek, S L Slager and C A Hanson

Leukemia 2012 26: 373-376; advance online publication, August 12, 2011; 10.1038/leu.2011.211

Comparison of childhood leukemia initiating cell populations in NOD/SCID and NSG mice

P Diamanti, C V Cox and A Blair

Leukemia 2012 26: 376-380; advance online publication, August 23, 2011; 10.1038/leu.2011.212